(Q34486262)

English

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study (English)

1 reference

Europe PubMed Central

2 August 2017

interstitial lung disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Paolo Fraticelli

object named as

Paolo Fraticelli

1

0 references

Gianluca Moroncini

object named as

Gianluca Moroncini

16

0 references

object named as

Maria Gerosa

7

0 references

Nicoletta Del Papa

object named as

Nicoletta Del Papa

10

0 references

Roberto Giacomelli

object named as

Roberto Giacomelli

9

0 references

Gabriele Valentini

object named as

Gabriele Valentini

4

0 references

object named as

Walter Malorni

14

0 references

Stefano Bombardieri

13

object named as

Stefano Bombardieri

1 reference

Europe PubMed Central

2 August 2017

11

object named as

Roberto Gerli

1 reference

Europe PubMed Central

2 August 2017

1 reference

ORCID Public Data File 2021

author name string

Barbara Gabrielli

2

1 reference

Europe PubMed Central

2 August 2017

Giovanni Pomponio

3

1 reference

Europe PubMed Central

2 August 2017

Silvia Bosello

5

1 reference

Europe PubMed Central

2 August 2017

Piersandro Riboldi

6

1 reference

Europe PubMed Central

2 August 2017

Paola Faggioli

8

1 reference

Europe PubMed Central

2 August 2017

Claudio Lunardi

12

1 reference

Europe PubMed Central

2 August 2017

Angelo Corvetta

15

1 reference

Europe PubMed Central

2 August 2017

Armando Gabrielli

17

1 reference

Europe PubMed Central

2 August 2017

Imatinib in Scleroderma Italian Study Group

18

1 reference

Europe PubMed Central

2 August 2017

publication date

8 July 2014

1 reference

Europe PubMed Central

2 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

2 August 2017

16

1 reference

Europe PubMed Central

2 August 2017

4

1 reference

Europe PubMed Central

2 August 2017

R144

1 reference

Europe PubMed Central

2 August 2017

https://scigraph.springernature.com/pub.10.1186/ar4606

0 references

Imatinib: novel treatment of immune-mediated kidney injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Changes in causes of death in systemic sclerosis, 1972-2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Standardisation of the single-breath determination of carbon monoxide uptake in the lung

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Standardisation of the measurement of lung volumes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Interstitial lung disease in scleroderma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

6 July 2018

Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227120

27 October 2018

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25007944

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25007944

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography

1 reference

https://pubmed.ncbi.nlm.nih.gov/25007944

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural course of progressive systemic sclerosis patients with interstitial lung involvement

1 reference

https://pubmed.ncbi.nlm.nih.gov/25007944

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34486262&oldid=1940279526"